Plus Therapeutics to Present at the 2022 Q2 Investor Summit
April 26 2022 - 7:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage
pharmaceutical company developing innovative, targeted
radiotherapeutics for rare and difficult-to-treat cancers,
announced today that Marc Hedrick, M.D., President and Chief
Executive Officer, will present at the 2022 Q2 Investor Summit on
Tuesday, May 3, 2022, at 12:30 p.m. ET at the Westin New York Grand
Central, New York, N.Y.
Investors interested in arranging a meeting with
the Company’s management during the conference should contact the
Investor Summit conference coordinator. A webcast of the
presentation will be available under the For Investors tab of the
Plus website at www.plustherapeutics.com. A webcast replay will
also be accessible for 90 days following the event.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage
pharmaceutical company focused on the development, manufacture, and
commercialization of complex and innovative treatments for patients
battling cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is
currently centered around the enhanced delivery of a variety of
drugs using novel liposomal encapsulation technology. Liposomal
encapsulation has been extensively explored and undergone
significant technical and commercial advances since it was first
developed. Our platform is designed to facilitate new delivery
approaches and/or formulations of safe and effective, injectable
drugs, potentially enhancing the safety, efficacy and convenience
for patients and healthcare providers. More information may be
found at PlusTherapeutics.com and ReSPECT-Trials.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains statements that may
be deemed “forward-looking statements” within the meaning of U.S.
securities laws. All statements in this press release other than
statements of historical fact are forward-looking statements. These
forward-looking statements may be identified by future verbs, as
well as terms such as “designed to,” “will,” “can,” “potential,”
“focus,” “preparing,” “next steps,” “possibly,” and similar
expressions or the negatives thereof. Such statements are based
upon certain assumptions and assessments made by management in
light of their experience and their perception of historical
trends, current conditions, expected future developments and other
factors they believe to be appropriate. These statements include,
without limitation, statements regarding the following: the
potential promise of 186RNL including the ability of 186RNL to
safely and effectively deliver radiation directly to the tumor at
high doses; expectations as to the Company’s future performance
including the next steps in developing the Company’s current
assets; the Company’s clinical trials including statements
regarding the timing and characteristics of the ReSPECT-LM or the
ReSPECT-PBC trials; possible negative effects of 186RNL; the
continued evaluation of 186RNL including through evaluations via a
seventh patient cohort; and the intended functions of the Company’s
platform and expected benefits from such functions.
The forward-looking statements included in this
press release are subject to a number of risks and uncertainties
that may cause actual results to differ materially from those
discussed in such forward-looking statements. These risks and
uncertainties include, but are not limited to: the Company’s actual
results may differ, including materially, from those anticipated in
these forward-looking statements as a result of various factors,
including, but not limited to, the following: the early stage of
the Company’s product candidates and therapies, the results of the
Company’s research and development activities, including
uncertainties relating to the clinical trials of its product
candidates and therapies; the Company’s liquidity and capital
resources and its ability to raise additional cash, the outcome of
the Company’s partnering/licensing efforts, risks associated with
laws or regulatory requirements applicable to it, market
conditions, product performance, litigation or potential
litigation, and competition within the regenerative medicine field,
among others; and additional risks described under the heading
“Risk Factors” in the Company’s Securities and Exchange Commission
filings, including in the Company’s annual and quarterly reports.
There may be events in the future that the Company is unable to
predict, or over which it has no control, and its business,
financial condition, results of operations and prospects may change
in the future. The Company assumes no responsibility to update or
revise any forward-looking statements to reflect events, trends or
circumstances after the date they are made unless the Company has
an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter VozzoICR Westwicke(443)
377-4767Peter.Vozzo@westwicke.com
Media Contact
Terri ClevengerICR Westwicke(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Sep 2023 to Sep 2024